TRUQAP (capivasertib), FDA Approved for the Treatment of Breast Cancer, Available at Biologics by McKesson
Biologics by McKesson was selected as a specialty pharmacy provider for TRUQAP, approved with fulvestrant for certain biomarker-altered HR-positive, HER2-negative advanced or metastatic breast cancer.